Trellis's Biofilm Buster: A New Front in the War on Superbugs

REDWOOD CITY, Calif. – July 16, 2026 – In the quiet corridors of biotechnology, where the future of medicine is forged, a significant financial endorsement has just amplified the signal of a potential breakthrough. Trellis Bioscience, a clinical-stage company, announced today the closing of a $9 million Series C financing round. While funding rounds are a daily occurrence in Silicon Valley, this one warrants special attention. The capital is designated for advancing Calpurbatug (TRL1068), a novel antibody treatment aimed at one of modern medicine's most stubborn and devastating complications: chronic prosthetic joint infections (PJI).

This isn't merely a story about a promising drug; it's about a strategic shift in our protracted war against antimicrobial resistance (AMR). The investment, led by specialized players like the AMR Action Fund, signals a growing confidence in attacking not just the bacteria themselves, but the fortresses they build to survive.

The Hidden Fortress of Infection

For the more than 25,000 patients in the U.S. who suffer from PJI annually, the experience is often grueling. What begins as a life-improving hip or knee replacement can spiral into a debilitating cycle of pain, surgery, and despair. These infections are notoriously difficult to treat because the bacteria form a biofilm—a slimy, protective matrix—on the surface of the implant. This biofilm acts as a shield, rendering even potent antibiotics ineffective and hiding the pathogens from the body's immune system.

The current standard of care is a brutal, two-stage surgical revision. The infected joint is removed, the area is cleaned, an antibiotic-laced spacer is inserted, and the patient endures weeks or months of high-dose antibiotics before a second major surgery to implant a new prosthesis. The process is physically and emotionally taxing, with high failure rates and a five-year mortality rate that some studies suggest is comparable to or even higher than that of common cancers. The financial burden is equally staggering, with the cost of managing a single PJI case capable of exceeding $400,000, contributing to an estimated $1.85 billion in annual U.S. hospital costs by 2030.

"Infection is a risk with any surgical procedure, and prosthetic joint infections can be devastating for patients," said Henry Skinner, PhD, CEO of AMR Action Fund. "The growing threat of antimicrobial resistance is making these infections increasingly difficult to treat."

A New Weapon in the Antimicrobial Arsenal

Trellis Bioscience is proposing a radical departure from the current paradigm. Instead of trying to bombard the bacterial fortress with more firepower, Calpurbatug is designed to dismantle its walls. The therapy is a native human monoclonal antibody that targets a conserved protein essential for the structural integrity of the biofilm. By binding to this protein, it effectively disassembles the protective matrix, exposing the once-shielded bacteria to the full force of standard antibiotics.

"By disrupting bacterial biofilm, calpurbatug represents a new class of agents with potential utility in a substantial number of antibiotic-resistant infections," said Trellis CEO Geoff Dillon. This approach could augment a much less invasive procedure known as DAIR (debridement, antibiotics, and implant retention), potentially allowing patients to keep their original implant.

Early clinical data provides a compelling proof of concept. In its Phase 1 trial, Calpurbatug was well-tolerated and demonstrated a remarkable ability to disrupt biofilms. In a planned interim analysis, 75% of patients treated with a single dose of the antibody alongside standard antibiotics saw their biofilm burden drop significantly after just seven days. For a quarter of those patients, the biofilm was eliminated below the level of detection. These are promising signals for a condition that has long been a surgical nightmare.

Jason Adams of The Doctor Group, a new investor, noted the transformative potential: "The emerging results from clinical trials for augmenting the DAIR procedure with TRL1068 suggest that this innovative drug will yield outcomes superior to two-stage revision... That would be a true game changer in the field — better results and less grueling for the patient."

Strategic Capital Signals a Turning Point

The composition of the investor syndicate is as telling as the technology itself. The participation of the AMR Action Fund, a venture created by leading pharmaceutical companies to combat superbugs, is a powerful vote of confidence. Their investment comes with strategic value, as evidenced by the appointment of AMRAF Principal Junjun Gao, PhD, to the Trellis Board of Directors. This move embeds deep sector expertise directly into the company's leadership.

Furthermore, the inclusion of The Doctor Group and practicing orthopedic surgeons from top U.S. centers indicates that the medical community sees a clear clinical need and a viable path forward. This is not just venture capital chasing a high-multiple exit; it is informed, strategic capital recognizing a solution to a pressing real-world problem.

"The PJI treatment challenge and financial burden are expanding as more joint replacement surgeries are expected for the aging U.S. population," commented John Friedman, Chairman of Easton Capital, a returning investor. This long-term demographic trend underpins the growing market and urgent need for innovation in the space.

Navigating the Path to Market

Trellis has been astute in navigating the complex regulatory landscape. Calpurbatug has already received Orphan Drug, Fast Track, and Qualified Infectious Disease Product (QIDP) designations from the FDA. These are not mere accolades; they are critical tools that de-risk and accelerate development. Fast Track ensures more frequent communication with the FDA, while the QIDP and Orphan Drug designations provide a combined 12 years of potential market exclusivity upon approval. This extended protection is a crucial incentive in the high-risk, low-reward environment that has historically plagued antibiotic development.

With its Phase 2 trial now fully enrolled, the company is on a clear path toward its next major inflection point. Top-line results, expected in the second quarter of 2027, will be scrutinized by investors, clinicians, and regulators alike. If the data confirms the promise shown in early trials, Trellis Bioscience will not only have a powerful new therapy for a devastating condition but will have validated a new strategy in the global fight against intractable infections.